Research progress of long non-coding RNA metastasis-associated lung adenocarcinoma transcript 1 in diabetic retinopathy_Chinese Journal of Ocular Fundus Diseases

Authors：

Hu Bin ¹ ,  Tian Yanming ²

1. Graduate School, Shihezi University, Shihezi 832003, China;
2. Department of Ophthalmology, General Hospital of Xinjiang Military Region, Urumqi 834000, China;

Corresponding author：

Tian Yanming, Email: tianyanming@163.com

Keywords：

Diabetic retinopathy; Long non-coding RNA; MALAT1; Molecular mechanism; Review

DOI：

10.3760/cma.j.cn511434-20240626-00241

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Diabetic retinopathy (DR) is a serious complication of diabetes mellitus that not only impairs vision and quality of life but has also emerged as a leading cause of blindness in working-age individuals. Long non-coding RNA metastasis-associated lung adenocarcinoma transcript 1 (LncMALAT1) is a non-coding RNA molecule that regulates gene expression and has been implicated in the pathogenesis and progression of DR. It exerts its effects through the modulation of various pathological processes, including inflammation, oxidative stress, angiogenesis, and apoptosis. Notably, alterations in the expression levels of LncMALAT1 may serve as potential biomarkers for the early diagnosis of DR. Furthermore, interventions targeting LncMALAT1, employing antioxidants, anti-angiogenic agents, traditional Chinese medicine, and gene therapy, present promising avenues for its potential development as an effective therapeutic target for DR.

Citation： Hu Bin, Tian Yanming. Research progress of long non-coding RNA metastasis-associated lung adenocarcinoma transcript 1 in diabetic retinopathy. Chinese Journal of Ocular Fundus Diseases, 2025, 41(1): 76-80. doi: 10.3760/cma.j.cn511434-20240626-00241 Copy

1.
2.
3.	Sun H, Saeedi P, Karuranga S, et al. IDF diabetes atlas: global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045[J/OL]. Diabetes Res Clin Pract, 2022, 183: 109119[2021-12-06]. https://pubmed.ncbi.nlm.nih.gov/34879977/. DOI: 10.1016/j.diabres.2023.110945.
4.
5.
6.	Geng M, Liu W, Li J, et al. LncRNA as a regulator in the development of diabetic complications[J/OL]. Front Endocrinol (Lausanne), 2024, 15: 1324393[2024-02-08]. https://pubmed.ncbi.nlm.nih.gov/38390204/. DOI: 10.3389/fendo.2024.1324393.
7.
8.
9.	Su Y, Wu H, Pavlosky A, et al. Regulatory non-coding RNA: new instruments in the orchestration of cell death[J/OL]. Cell Death Dis, 2016, 7(8): e2333[2016-08-11]. https://pubmed.ncbi.nlm.nih.gov/27512954/. DOI: 10.1038/cddis.2016.210.
10.
11.	Biswas S, Thomas AA, Chen S, et al. MALAT1: An epigenetic regulator of Inflammation in diabetic retinopathy[J/OL]. Sci Rep, 2018, 8(1): 6526[2018-04-25]. https://pubmed.ncbi.nlm.nih.gov/29695738/. DOI: 10.1038/s41598-018-24907-w.
12.	Liu JY, Yao J, Li XM, et al. Pathogenic role of lncRNA-MALAT1 in endothelial cell dysfunction in diabetes mellitus[J/OL]. Cell Death Dis, 2014, 5(10): e1506[2014-10-30]. https://pubmed.ncbi.nlm.nih.gov/25356875/. DOI: 10.1038/cddis.2014.466.
13.
14.
15.	Haydinger CD, Oliver GF, Ashander LM, et al. Oxidative stress and its regulation in diabetic retinopathy[J/OL]. Antioxidants (Basel), 2023, 12(8): 1649[2023-08-21]. https://pubmed.ncbi.nlm.nih.gov/37627644/. DOI: 10.3390/antiox12081649.
16.	Kang Q, Yang C. Oxidative stress and diabetic retinopathy: Molecular mechanisms, pathogenetic role and therapeutic implications[J/OL]. Redox Biol, 2020, 37: 101799[2020-11-13]. https://pubmed.ncbi.nlm.nih.gov/33248932/. DOI: 10.1016/j.redox.2020.101799.
17.	Tian Y, Cheng W, Wang H, et al. Ascorbic acid protects retinal pigment epithelial cells from high glucose by inhibiting the NF-κB signal pathway through MALAT1/IGF2BP3 axis[J/OL]. Diabet Med, 2023, 40(5): e15050[2023-01-20]. https://pubmed.ncbi.nlm.nih.gov/36661363/. DOI: 10.1111/dme.15050.
18.
19.	Wang Y, Wang L, Guo H, et al. Knockdown of MALAT1 attenuates high-glucose-induced angiogenesis and inflammation via endoplasmic reticulum stress in human retinal vascular endothelial cells[J/OL]. Biomed Pharmacother, 2020, 124: 109699[2020-01-25]. https://pubmed.ncbi.nlm.nih.gov/31986419/. DOI: 10.1016/j.biopha.2019.109699.
20.
21.
22.
23.
24.
25.	Chen Z, Yang J, Gao Y, et al. LncRNA MALAT1 aggravates the retinal angiogenesis via miR-320a/HIF-1α axis in diabetic retinopathy[J/OL]. Exp Eye Res, 2022, 218: 108984[2022-02-21]. https://pubmed.ncbi.nlm.nih.gov/35202706/. DOI: 10.1016/j.exer.2022.108984.
26.
27.	Tan A, Li T, Ruan L, et al. Knockdown of malat1 alleviates high-glucose-induced angiogenesis through regulating miR-205-5p/VEGF-A axis[J/OL]. Exp Eye Res, 2021, 207: 1085859[2021-04-20]. https://pubmed.ncbi.nlm.nih.gov/33887222/. DOI: 10.1016/j.exer.2021.108585.
28.
29.	Liu P, Jia SB, Shi JM, et al. LncRNA-MALAT1 promotes neovascularization in diabetic retinopathy through regulating miR-125b/VE-cadherin axis[J/OL]. Biosci Rep, 2019, 39(5): BSR20181469[2019-05-15]. https://pubmed.ncbi.nlm.nih.gov/30988072/. DOI: 10.1042/BSR20181469.
30.
31.
32.
33.
34.	Zhou LJ, Yang DW, Ou LN, et al. Circulating expression level of lncRNA Malat1 in diabetic kidney disease patients and its clinical significance[J/OL]. J Diabetes Res, 2020, 2020: 4729019[2020-08-01]. https://pubmed.ncbi.nlm.nih.gov/32832561/. DOI: 10.1155/2020/4729019.
35.	Su X, Huang H, Lai J, et al. Long noncoding RNAs as potential diagnostic biomarkers for diabetes mellitus and complications: a systematic review and meta-analysis[J/OL]. J Diabetes, 2023, 16(2): e13510[2023-12-23]. https://pubmed.ncbi.nlm.nih.gov/38140829/. DOI: 10.1111/1753-0407.13510.
36.
37.
38.	Biswas S, Coyle A, Chen S, et al. Expressions of serum incRNAs in diabetic retinopathy-a potential diagnostic tool[J/OL]. Front Endocrinol (Lausanne), 2022, 13: 851967[2022-04-07]. https://pubmed.ncbi.nlm.nih.gov/35464068/. DOI: 10.3389/fendo.2022.851967.
39.
40.
41.	Di S, An X, Pang B, et al. Yiqi Tongluo Fang could preventive and delayed development and formation of diabetic retinopathy through antioxidant and anti-inflammatory effects[J/OL]. Biomed Pharmacother, 2022, 148: 112254[2022-02-17]. https://pubmed.ncbi.nlm.nih.gov/35183405/. DOI: 10.1016/j.biopha.2021.112254.
42.
43.	Davodabadi F, Farasati Far B, Sargazi S, et al. Nanomaterials-based targeting of long non-coding RNAs in cancer: a cutting-edge review of current trends[J/OL]. ChemMedChem, 2024, 19(8): e202300528[2024-01-24]. https://pubmed.ncbi.nlm.nih.gov/38267373/. DOI: 10.1002/cmdc.202300528.
44.	Shyu KG, Wang BW, Fang WJ, et al. Exosomal MALAT1 derived from high glucose-treated macrophages up-regulates resistin expression via miR-150-5p downregulation[J/OL]. Int J Mol Sci, 2022, 23(3): 1095[2022-01-20]. https://pubmed.ncbi.nlm.nih.gov/35163020/. DOI: 10.3390/ijms23031095.
45.
46.

1.
2.
3. Sun H, Saeedi P, Karuranga S, et al. IDF diabetes atlas: global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045[J/OL]. Diabetes Res Clin Pract, 2022, 183: 109119[2021-12-06]. https://pubmed.ncbi.nlm.nih.gov/34879977/. DOI: 10.1016/j.diabres.2023.110945.
4.
5.
6. Geng M, Liu W, Li J, et al. LncRNA as a regulator in the development of diabetic complications[J/OL]. Front Endocrinol (Lausanne), 2024, 15: 1324393[2024-02-08]. https://pubmed.ncbi.nlm.nih.gov/38390204/. DOI: 10.3389/fendo.2024.1324393.
7.
8.
9. Su Y, Wu H, Pavlosky A, et al. Regulatory non-coding RNA: new instruments in the orchestration of cell death[J/OL]. Cell Death Dis, 2016, 7(8): e2333[2016-08-11]. https://pubmed.ncbi.nlm.nih.gov/27512954/. DOI: 10.1038/cddis.2016.210.
10.
11. Biswas S, Thomas AA, Chen S, et al. MALAT1: An epigenetic regulator of Inflammation in diabetic retinopathy[J/OL]. Sci Rep, 2018, 8(1): 6526[2018-04-25]. https://pubmed.ncbi.nlm.nih.gov/29695738/. DOI: 10.1038/s41598-018-24907-w.
12. Liu JY, Yao J, Li XM, et al. Pathogenic role of lncRNA-MALAT1 in endothelial cell dysfunction in diabetes mellitus[J/OL]. Cell Death Dis, 2014, 5(10): e1506[2014-10-30]. https://pubmed.ncbi.nlm.nih.gov/25356875/. DOI: 10.1038/cddis.2014.466.
13.
14.
15. Haydinger CD, Oliver GF, Ashander LM, et al. Oxidative stress and its regulation in diabetic retinopathy[J/OL]. Antioxidants (Basel), 2023, 12(8): 1649[2023-08-21]. https://pubmed.ncbi.nlm.nih.gov/37627644/. DOI: 10.3390/antiox12081649.
16. Kang Q, Yang C. Oxidative stress and diabetic retinopathy: Molecular mechanisms, pathogenetic role and therapeutic implications[J/OL]. Redox Biol, 2020, 37: 101799[2020-11-13]. https://pubmed.ncbi.nlm.nih.gov/33248932/. DOI: 10.1016/j.redox.2020.101799.
17. Tian Y, Cheng W, Wang H, et al. Ascorbic acid protects retinal pigment epithelial cells from high glucose by inhibiting the NF-κB signal pathway through MALAT1/IGF2BP3 axis[J/OL]. Diabet Med, 2023, 40(5): e15050[2023-01-20]. https://pubmed.ncbi.nlm.nih.gov/36661363/. DOI: 10.1111/dme.15050.
18.
19. Wang Y, Wang L, Guo H, et al. Knockdown of MALAT1 attenuates high-glucose-induced angiogenesis and inflammation via endoplasmic reticulum stress in human retinal vascular endothelial cells[J/OL]. Biomed Pharmacother, 2020, 124: 109699[2020-01-25]. https://pubmed.ncbi.nlm.nih.gov/31986419/. DOI: 10.1016/j.biopha.2019.109699.
20.
21.
22.
23.
24.
25. Chen Z, Yang J, Gao Y, et al. LncRNA MALAT1 aggravates the retinal angiogenesis via miR-320a/HIF-1α axis in diabetic retinopathy[J/OL]. Exp Eye Res, 2022, 218: 108984[2022-02-21]. https://pubmed.ncbi.nlm.nih.gov/35202706/. DOI: 10.1016/j.exer.2022.108984.
26.
27. Tan A, Li T, Ruan L, et al. Knockdown of malat1 alleviates high-glucose-induced angiogenesis through regulating miR-205-5p/VEGF-A axis[J/OL]. Exp Eye Res, 2021, 207: 1085859[2021-04-20]. https://pubmed.ncbi.nlm.nih.gov/33887222/. DOI: 10.1016/j.exer.2021.108585.
28.
29. Liu P, Jia SB, Shi JM, et al. LncRNA-MALAT1 promotes neovascularization in diabetic retinopathy through regulating miR-125b/VE-cadherin axis[J/OL]. Biosci Rep, 2019, 39(5): BSR20181469[2019-05-15]. https://pubmed.ncbi.nlm.nih.gov/30988072/. DOI: 10.1042/BSR20181469.
30.
31.
32.
33.
34. Zhou LJ, Yang DW, Ou LN, et al. Circulating expression level of lncRNA Malat1 in diabetic kidney disease patients and its clinical significance[J/OL]. J Diabetes Res, 2020, 2020: 4729019[2020-08-01]. https://pubmed.ncbi.nlm.nih.gov/32832561/. DOI: 10.1155/2020/4729019.
35. Su X, Huang H, Lai J, et al. Long noncoding RNAs as potential diagnostic biomarkers for diabetes mellitus and complications: a systematic review and meta-analysis[J/OL]. J Diabetes, 2023, 16(2): e13510[2023-12-23]. https://pubmed.ncbi.nlm.nih.gov/38140829/. DOI: 10.1111/1753-0407.13510.
36.
37.
38. Biswas S, Coyle A, Chen S, et al. Expressions of serum incRNAs in diabetic retinopathy-a potential diagnostic tool[J/OL]. Front Endocrinol (Lausanne), 2022, 13: 851967[2022-04-07]. https://pubmed.ncbi.nlm.nih.gov/35464068/. DOI: 10.3389/fendo.2022.851967.
39.
40.
41. Di S, An X, Pang B, et al. Yiqi Tongluo Fang could preventive and delayed development and formation of diabetic retinopathy through antioxidant and anti-inflammatory effects[J/OL]. Biomed Pharmacother, 2022, 148: 112254[2022-02-17]. https://pubmed.ncbi.nlm.nih.gov/35183405/. DOI: 10.1016/j.biopha.2021.112254.
42.
43. Davodabadi F, Farasati Far B, Sargazi S, et al. Nanomaterials-based targeting of long non-coding RNAs in cancer: a cutting-edge review of current trends[J/OL]. ChemMedChem, 2024, 19(8): e202300528[2024-01-24]. https://pubmed.ncbi.nlm.nih.gov/38267373/. DOI: 10.1002/cmdc.202300528.
44. Shyu KG, Wang BW, Fang WJ, et al. Exosomal MALAT1 derived from high glucose-treated macrophages up-regulates resistin expression via miR-150-5p downregulation[J/OL]. Int J Mol Sci, 2022, 23(3): 1095[2022-01-20]. https://pubmed.ncbi.nlm.nih.gov/35163020/. DOI: 10.3390/ijms23031095.
45.
46.

Previous Article
The short-term effects of Conbercept intravitreal injection on matrix metalloproteinase-2 and tissue inhibitor of metalloproteinases-2 expression in the aqueous humor of eyes with proliferative diabetic retinopathy

Chinese Journal of Ocular Fundus Diseases

Research progress of long non-coding RNA metastasis-associated lung adenocarcinoma transcript 1 in diabetic retinopathy

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Format

Content